Abbreviations used in this paper: eNOS = endothelial nitric oxide synthase; FOXO = Forkhead transcription factor; IκB = inhibitory-κB; mNSS = modified Neurological Severity Score; NF-κB = nu clear factor-κB; pNA = p-nitroaniline; SD = standard deviation; TBI = traumatic brain injury; TUNEL = terminal deoxynucleotidyl nick-end labeling.
Activated Akt phosphorylates several downstream signaling target proteins, including Bad, glycogen synthase kinase 3-β, FOXOs, and IκB to control cell growth, cell survival, and protein synthesis. The FOXOs regulate the transcription of the cell cycle inhibitor p27 as well as the proapoptotic Fas ligand and the Bcl-2-like protein Bim. 12 Phosphorylation of IκB leads to its dissociation and activation of NF-κB, which induces the expression of several genes that promote neuron survival, including those encoding manganese superoxide dismutase, inhibitor-ofapoptosis proteins, Akt, Bcl-2, and calbindin. 23 In this study we investigated the effects of simvastatin on apoptotic cell death after TBI. To examine a possible mechanism for the neuroprotective effects of simvastatin that subsequently enhanced the functional recovery, we focused on the Akt pathway, which has been implicated in the survival of neuronal cells. 32 
Methods

Animal Models
In the present study we used a modified controlled cortical injury model of TBI in rats. 22 All experimental procedures were approved by the Institutional Animal Care and Use Committee of Henry Ford Hospital.
Adult male Wistar rats weighing 300-400 g were anesthetized intraperitoneally with 350 mg/kg body weight chloral hydrate. Rectal temperature was maintained at 37°C by using a feedback-regulated water heating pad. A controlled cortical injury device was used to induce injury. The rats were placed in a stereotactic frame. Two 10-mmdiameter craniotomies were performed adjacent to the central suture, midway between the lambda and the bregma. The second craniotomy allowed for lateral movement of cortical tissue. The dura mater was kept intact over the cortex. Injury was induced by striking the left cortex (ipsilateral cortex) with a pneumatic piston containing a 6-mmdiameter tip at a rate of 4 m/second and exerting 2.5 mm of compression. Velocity was measured using a linear velocity displacement transducer. Sham-injured animals were similarly anesthetized, and craniectomy was performed without cortical injury.
Experimental Groups
Male Wistar rats were randomly divided into 3 groups. Rats in Group 1 (40 rats) were exposed to TBI and given saline orally 1 day later and consecutively for 14 days. Rats in Group 2 (40 rats) were subjected to TBI, and 1 day later simvastatin was administered orally at a dose of 1 mg/kg/ day for 14 consecutive days. This dose was selected based on our previously reported study. 20 Rats in Group 3 (8 rats) were subjected to sham surgery. Neurological functional evaluation was performed on Days 1, 3, 7, 14, and 35 after TBI. Rats in the first and second groups were killed at 1, 3, 7, 14, and 35 days after administration of simvastatin, and rats in the sham group were killed 1 day after TBI. Sixteen animals were killed at each time point; 8 rats were used for immunohistochemical analysis, and the other 8 rats were used for Western blot analysis.
Neurological Functional Evaluation
Neurological functional measurement was performed using an mNSS. The mNSS is a composite of the motor (muscle status and abnormal movement), sensory (visual, tactile, and proprioceptive), and reflex tests. This test has been used in previous studies. 6, 19 Motor tests of the mNSS include 7 items with a maximum of 6 points. Sensory tests include 2 items with a maximum of 2 points. Beam Balance Tests have 7 items with a maximum score of 6. The last part of the mNSS includes the pinna, corneal, and start le reflexes and abnormal movements. Insult in the left hemisphere cortex of rats causes sensory and motor functional deficiency with elevated scores early after TBI.
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Tissue Preparation
For immunostaining, rats were anesthetized intraperi to neally with chloral hydrate (350 mg/kg), and perfused trans cardially with saline, followed by 4% paraformaldehyde. Brains were isolated, postfixed in 4% par aformaldehyde for 2 days at room temperature, and then processed for paraffin sectioning. A series of 10-μm-thick sections were cut with a microtome through each of 7 standard sections. For biochemical analysis, the ipsilateral and contralateral cortex and hippocampus tissues were dissected, frozen in liquid nitrogen, and stored at −80°C until use.
The TUNEL Staining
To identify cellular apoptosis, TUNEL was performed using an ApopTag peroxidase in situ apoptosis detection Kit (Chemicon). The paraffin-embedded coronal sections at the level of the hippocampus and dentate gyrus were selected and processed for TUNEL staining. After the digesting and quenching steps, equilibration buffer was applied directly to the sections, and working-strength TdT enzyme was then applied directly. A biotin-conjugated antidi goxigenin antibody was used. The sections were then incubated with biotinylated secondary antibody at 1:100 dilution for 45 minutes at room temperature and later with horseradish peroxidase-labeled streptavidin at 1:100 dilution for 45 minutes at room temperature. After a brief wash, 3,3′-diaminobenzidine tetrahydrochloride (0.5 mg/ ml)/H 2 O 2 (0.01%), a chromogen substrate, was incorporated. To quantify apoptotic neuronal cells in different areas, 10 consecutive fields were randomly selected and evaluated at 400 × using an imaging analyzer. A blind-counting method was used to count TUNEL-positive cell numbers. For counting, images were obtained from the cortex, hippocampus, and dentate gyrus of the ipsilateral side of the injured animals. In each image we manually counted the TUNEL-positive cells from the boundary zone in the cortex, the CA3 region in the hippocampus, and the body and hilus of the dentate gyrus.
Caspase-3 Activity Assay
The activity of caspase-3 was determined using an Apo-Alert colorimetric caspase-3 assay kit (BD Biosciences Clontech). Brain cortex tissues in the boundary zone were collected and lysed in lysis buffer and equal amounts of lysates were used for caspase-3 activity assay, which was measured at a wavelength of 405 nm using the detection of chromophore pNA after its cleavage by caspase-3 from the labeled caspase-3 specific substrate, DEVD-pNA. The data are presented as pmoles of pNA per microgram of cell lysate per hour of incubation.
Western Blot Analysis
Rats in Groups 1 and 2 were killed at Days 1, 3, 7, 14, and 35 after administration of simvastatin (4 rats/ time point/group). Brain tissues from the lesion boundary zone and the hippocampus were collected, washed once in 1 × phosphate-buffered saline and lysed in lysis buffer (20 mM Tris pH 7.6, 100 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 1% deoxycholic acid, 10% glycerol, 1 mM ethylenediamine tetraacetic acid, 1 mM NaVO 3 , 50 mM NaF, cocktail I of protease inhibitors from Calbiochem). After sonication, soluble protein was obtained by centrifugation at 13,000 G for 15 minutes at 4°C. The protein concentration of each sample was determined by bicinchoninic acid protein assay (Pierce). For immunoblotting, equal amounts of cell lysate were subjected to sodium dodecyl sulfate-polyacrylamide electrophor esis on Novex Tris-Glycine precast gels (Invitrogen) and separated proteins were then electrotransferred to polyvinylidene fluoride membranes. Membranes were blocked with 2% I-Block (Applied Biosystems) in phosphate-buffered saline plus 0.1% Tween 20 for 1 hour at room temperature and then incubated with different primary antibodies overnight at 4°C. We used the following antibodies: anti-phosphorylated eNOS (Ser1177), antiphosphorylated FOXO1 (Ser256), and anti-phosphorylated IκB (Ser32) (1:1000 dilution, Cell Signaling Technology); anti-phosphorylated Akt (Ser473) and anti-Actin (I-19) (1:1000; Santa Cruz Biotechnology). After washing, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:2500; Jackson ImmunoResearch Laboratories) in blocking buffer for 2 hours at room temperature. Specific proteins were visualized using SuperSignal West Pico chemiluminescence substrate system (Pierce). The intensity of the bands was measured using Scion image analysis (Scion Corp.).
Statistical Analysis
All data are presented as means ± SDs. Data were analyzed using a one-way analysis of variance. Differences were determined to be significant at a probability value < 0.05. All measurements were performed by observers blinded to individual treatments.
Results
Simvastatin Enhances the Recovery of Sensorimotor Function After TBI
Injury in the left hemisphere cortex of rats causes neurological functional deficits as measured by the mNSS. These rats presented with high scores on motor, sensory, and Beam Balance Tests on Day 1 after injury. Absent reflexes and abnormal movements were evident in rats with severe injury. On Day 3 after injury, recovery began, and this recovery persisted at all subsequent evaluation time points in both saline-treated and simvastatin-treated groups.
Motor function tested by the mNSS recovered faster than sensory and beam balance functions. By Day 14 after injury, residual deficit scores were present mainly on the Beam Balance Tests and sensory (placing) test of the mNSS. The mNSS scores for the simvastatin-treated group were significantly decreased at Days 7 and 14 (6.2 ± 1.2 and 5.0 ± 0.6, respectively; p < 0.05) after TBI when compared with the saline-treated groups (8.2 ± 0.9 and 7.1 ± 0.7, respectively; p < 0.05) (Fig. 1) .
Simvastatin Reduces TUNEL-Positive Cells
The TUNEL staining has been used extensively to identify cells with nuclear DNA fragmentation.
29 Cells were scored as apoptotic when they were TUNEL-positive (brown staining in Fig. 2a-l) and showed nuclear chromatin condensation (Fig. 2a) . In each hemispheric section of the sham-operated rats and in the contralateral hemisphere of ischemic rats, cells were almost negative for TUNEL staining, with only 0-3 TUNEL-positive cells. Those cells with nuclei not stained with TUNEL (TUNEL-negative, blue color in Fig. 2a-l) were visualized by counterstaining with hematoxylin. In contrast, in the ipsilateral hemisphere in the saline-treated control group, a large number of TUNEL-positive cells, which were mainly located in the ipsilateral boundary cortex, hip pocampus, and dentate gyrus, were seen at 24 hours af ter TBI. Compared with the saline-treated group simvastatin reduced the number of TUNEL-positive cells (74 ± 6.8 vs 52 ± 4.6 in the lesion boundary zone, p < 0.05; 15 ± 4.5 vs 6 ± 2.1 in the hippocampus, p < 0.01) notable on Day 3 after treatment ( Fig. 2o and m) , demonstrating that simvastatin reduces apoptosis in the hippocampus and the lesion boundary zone after TBI. Fig. 1 . Graph showing the temporal profile of the mNSS after TBI in saline-or simvastatin-treated rats (8/group). The score was significantly decreased in the simvastatin-treated group compared with the saline-treated group from 7 days after treatment. These data demonstrate that simvastatin enhances the sensorimotor functional recovery after TBI. Data are represented as means ± SDs. * p < 0.05, ** p < 0.01.
Simvastatin Reduces Apoptotic Cell Death Through Suppression of Caspase-3 Activity
Caspase-3 activity was measured to determine if simvastatin suppressed the TBI-induced apoptosis via the caspase cascade, which is the central protease in the cell death pathway. Colorimetric assay showed a significant decrease in caspase-3 activity at Days 1 (28.56 ± 3.9 vs 19.45 ± 2.9, p < 0.05) and 3 (64.86 ± 13.98 vs 24.15 ± 12.01, p < 0.01) after simvastatin treatment (Fig. 3) , suggesting that simvastatin suppresses the cleavage of caspase-3.
Phosphorylation of Akt, eNOS, FOXO1, and IκB in the Ipsilateral Hemisphere Following Treatment With Simvastatin After TBI
We have previously shown that simvastatin signifi- cantly enhanced the phosphorylation of Akt on Day 1 of treatment, which was sustained until Day 7, with a peak at Day 3 (Fig. 4A) . Therefore, we investigated whether sim vastatin may phosphorylate and thereby activate/inactivate its downstream targets, such as FOXOs. Our data show that the phosphorylation of FOXO1 was increased in the simvastatin-treated group, which began at Day 1 and lasted to Day 7 after treatment (Fig. 4B) . The Aktdependent phosphorylation leads to the posttranslational activation of eNOS via phosphorylation of the amino acid Ser1177, which has been described as an important antiapoptotic signaling pathway in endothelial cells. 33 Western blot analysis showed a substantial increase of phosphorylated eNOS in the ipsilateral hemisphere after TBI, which has been described as an important antiapoptotic signaling pathway in endothelial cells. The levels of phosphorylated eNOS were significantly increased at Day 3 af ter simvastatin treatment (p < 0.05 at Day 3) (Fig. 4C) , re maining elevated at Day 7 (p < 0.01 at Day 7) and then declined to control level at Day 14. Because phosphorylation of IκB-α at Ser32 is essential for release of active NF-κB, phosphorylation at this site is an excellent marker of NF-κB activation. Western blot analysis showed an elevated phosphorylation of IκB-α at Ser32 from Days 1 to 7 after TBI (p < 0.05 at Days 1, 3, and 7).
Discussion
The primary findings in the present study are as follows: 1) treatment of TBI with simvastatin promotes the restoration of sensory motor function; 2) simvastatin suppresses activation of caspase-3 and protects the cells from apoptosis; and 3) simvastatin induces phosphorylation of Akt along with activation of the antiapoptotic IκB and eNOS, and inactivation of the proapoptotic FOXOs.
In the controlled cortical impact model of TBI, delayed neuronal cell death occurs in the boundary zone of the injured cortical area and the CA3 region of the hippocampus, in addition to the primary neuronal necrosis normally seen after injury. 15, 24 Both patterns of neuronal cell death may cause certain neuronal loss in these areas and subsequent neurological functional deficits in the animals. 11 These areas are potentially salvageable. Rescuing the damaged neurons in these areas promotes functional outcome after brain injury. 16 Therefore, neuronal survival in these areas is an important target to evaluate the degree of damaged brain tissue and the effect of therapeutic intervention. 25 In our current study, significant functional improvements in the simvastatin-treated group were detected by the mNSS at Days 7 and 14 after treatment when compared with the saline-treated control group. Significant functional improvement occurring at Day 7 after treatment suggests that simvastatin may rescue damaged neurons. This hypothesis was supported by the decreased numbers of TUNEL-positive cells in the boundary zone and the hippocampus in the ipsilateral hemisphere after simvastatin treatment (Fig. 3) .
To address the potential mechanisms by which simvastatin exerts its protective effects, we analyzed the caspase-3 activity in tissue samples obtained from different time points. Caspases, the ICE/CED-3 family of proteases, play a central role in the early stages of apoptosis. Of the identified caspases, caspase-3 is activated during apoptosis in many types of central nervous system cells, and its activation appears to be an important event in apoptosis. 28 Previous studies have shown increased apoptosis and caspase-3 activity in a rat TBI model. 7, 34 Simvastatin significantly decreased caspase-3 activities on Days 1 and 3 after treatment, suggesting that simvastatin inhibits the caspase-3 activation in the early phase. These results are consistent with previous data on the effect of simvastatin on caspase-3 activity in a hypoxia-ischemia model in the newborn rat. 5 Given that simvastatin may prevent apoptotic cell death through inhibition of caspase-3 activation, we further explored its underlying signaling pathway. The effect of simvastatin on phosphorylation of Akt has been reported in endothelial cells in vitro. 18 Recent studies have suggested that simvastatin induces the phosphorylation of Akt 6, 17 in the context of ischemic injury, which has also been confirmed in our previous study in a TBI model. Therefore, we tested the effect of simvastatin treatment on phosphorylation of Akt and its downstream targets eNOS, IκB, and FOXO1. Western blot analysis shows that simvastatin induces the phosphorylation of Akt, eNOS, IκB, and FOXO1 .
Because Akt phosphorylates FOXOs as downstream targets in cell survival signaling, 4, 30 we examined changes in FOXO1 phosphorylation as well as Akt phosphorylation after TBI. The FOXOs regulate the transcription of the cell cycle inhibitor p27 and the Bcl-2-like protein Bim, both of which are strong proapoptotic signaling proteins. 27 Akt phosphorylates and inactivates FOXO1 which prevents its translocation to the nucleus, thereby inhibiting apoptotic signaling. 30 The FOXO1 in neurons normally stays in the cytoplasm because of Akt-dependent phosphorylation. Once Akt activity is reduced by brain injury conditions, FOXO1 is dephosphorylated by undefined protein phosphatases. The dephosphorylation contributes to their importation into the nucleus through nuclear localization signals. The DNA-binding domain is required for activation of the promoters of Fas-ligand and Bim genes. 8, 12 Expression of the Fas-ligand gene induces caspase activation, which eventually leads to apoptosis. Simvastatin significantly increases phosphorylation of FOXO1 at an early phase in an Akt-dependent manner, and thereby, likely rescues neurons from apoptosis through phosphorylation and inactivation of FOXO1.
Nuclear factor-κB is widely known for its ubiquitous roles in the immune response as well as in control of cell 1 Functional NF-κB complexes are present in essentially all cell types in the nervous system, including neurons. 26 In its inactive form, NF-κB is present in cytosol as a 3-subunit complex, with the prototypical components being p65 and p50 and IκB (inhibitory subunit). Nuclear factor-κB is activated by signals that activate IκB kinase, resulting in phosphorylation of IκB; this targets IκB for degradation in the proteosome and frees the p65-p50 dimer, which then translocates to the nucleus and binds to consensus κB sequences in the promoter region of κB-responsive genes. The expression of several different genes that promote neuron survival is induced by NF-κB, including those encoding manganese superoxide dismutase (Mn-SOD), inhibitor-of-apoptosis proteins, and Bcl-2. These prosurvival proteins prevent the injured cells from undergoing the apoptotic process. Levels of NF-κB activity are increased in the cerebral cortex within hours of TBI in rats, after which they remain elevated for ≥ 24 hours. 23 Our data show that simvastatin elevates phosphorylation of IκB, which has been proven to promote the activation of NF-κB. 26 The elevated phosphorylation of IκB lasts for 7 days after simvastatin treatment, inducing a prolonged activation of NF-κB, which may mediate the antiapoptotic effect of simvastatin.
The Akt-dependent phosphorylation leads to the posttranslational activation of the eNOS via phosphorylation of the amino acid Ser1177, which has been described as an important antiapoptotic signaling pathway in endothelial cells. 9, 13, 36 Upregulated expression of eNOS leads to an increase in cerebral blood flow, smaller cerebral infarcts, and decreased neurological deficits in stroke. 10 Recent studies suggest that simvastatin can rapidly activate the protein kinase Akt/PKB in endothelial cells. Accordingly, simvastatin enhances phosphorylation of the endogenous Akt substrate eNOS and inhibits apoptosis in vitro in an Akt-dependent manner. 18 In the TBI model, we find a similar pattern of elevated phosphorylation of eNOS after treatment with simvastatin.
Conclusions
Based on our findings, we propose that treatment with simvastatin increases phosphorylation of Akt in the neuronal cells after TBI, followed by phosphorylation of its downstream targets FOXO, IκB, and eNOS, which eventually leads to antiapoptotic effects partially through suppressing caspase-3 activity.
Our data suggest that simvastatin suppresses apoptosis of neuronal cells and enhances the sensory-motor functional recovery post-TBI. The Akt/FOXO1/IκB/caspase-3 pathway may play a vital role in the neuroprotective effect of simvastatin treatment after TBI.
